Four-Dose Regimen Of 20-Valent Pneumococcal Conjugate Vaccine Elicits Robust Immunity In Healthy Infants, Study Finds

Infectious Disease Advisor (5/29, Nye) reports, “A 4-dose series of the 20-valent pneumococcal conjugate vaccine elicits a robust serotype-specific immune response and is well tolerated among healthy infants, according to study results published in The Pediatric Infectious Disease Journal.” In the study, “at 1 month after dose 3, the percentages of patients with prespecified IgG concentrations for 8 of the 13 matched serotypes were noninferior to the percentages for the corresponding serotypes in the 13-valent vaccine group. The responses to serotypes 1, 4, 9V, and 23F failed to reach noninferiority by small margins.” Patients then “showed substantial IgG boosting responses after receipt of dose 4 relative to those observed before dose 4 and after dose 3.”